Barclays PLC Verve Therapeutics, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Verve Therapeutics, Inc. stock. As of the latest transaction made, Barclays PLC holds 222,919 shares of VERV stock, worth $1.29 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

222,919

Previous 222,919 -0.0%

Holding current value

$1.29 Million

Previous $1.08 Million -0.0%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$4.4 - $7.86 $571,753 - $1.02 Million	129,944 Added 139.76%	222,919 $1.08 Million
Q2 2024 Aug 14, 2024	BUY	$4.76 - $12.79 $63,393 - $170,337	13,318 Added 16.72%	92,975 $454,000
Q1 2024 May 15, 2024	SELL	$10.81 - $17.96 $1.24 Million - $2.06 Million	-114,971 Reduced 59.07%	79,657 $1.06 Million
Q4 2023 Feb 15, 2024	BUY	$8.84 - $18.7 $445,624 - $942,667	50,410 Added 34.95%	194,628 $2.71 Million
Q3 2023 Nov 07, 2023	BUY	$11.42 - $20.82 $261,495 - $476,736	22,898 Added 18.87%	144,218 $1.91 Million
Q2 2023 Aug 03, 2023	BUY	$13.34 - $19.9 $166,403 - $248,232	12,474 Added 11.46%	121,320 $2.28 Million
Q1 2023 May 04, 2023	SELL	$14.3 - $24.01 $1.34 Million - $2.25 Million	-93,543 Reduced 46.22%	108,846 $1.57 Million
Q4 2022 Feb 13, 2023	BUY	$17.85 - $40.7 $1.58 Million - $3.61 Million	88,718 Added 78.05%	202,389 $3.92 Million
Q3 2022 Nov 03, 2022	BUY	$15.63 - $41.49 $1.7 Million - $4.51 Million	108,815 Added 2240.84%	113,671 $3.91 Million
Q2 2022 Aug 12, 2022	SELL	$11.14 - $23.17 $224,348 - $466,620	-20,139 Reduced 80.57%	4,856 $74,000
Q1 2022 May 16, 2022	BUY	$20.92 - $39.36 $522,895 - $983,803	24,995 New	24,995 $571,000

Others Institutions Holding VERV

# of Institutions

186

Shares Held

73.3M

Call Options Held

85K

Put Options Held

215K

View Full List

About Verve Therapeutics, Inc.

Ticker VERV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,942,300
Market Cap $346M
Description
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...

More about VERV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account